EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents

Clinical Microbiology and Infection

Volumn 22, Issue 6, 2016, Pages 571.e1-571.e4

  Arendrup, M C ^a,i   Meletiadis, J ^b,c,i   Mouton, J W ^c,d   Guinea, J ^e,i   Cuenca Estrella, M ^f   Lagrou, K ^g,i   Howard, S J ^h,i   Mouton, J ⁱ   Arikan Akdagli, S ⁱ   Barchiesi, F ⁱ   Hamal, P ⁱ   Jarv H ⁱ   Lass Florl C ⁱ   Mares, M ⁱ   Matos, T ⁱ   Muehlethaler, K ⁱ   Rogers, T R ⁱ   Torp Andersen, C ⁱ   Verweij, P ⁱ  

^a STATENS SERUM INSTITUT   (Denmark)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ NONE

Author keywords

Antifungal susceptibility testing; breakpoints; isavuconazole; itraconazole; QC MIC ranges

Indexed keywords

ISAVUCONAZOLE; ITRACONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; HUMAN; MEDICAL DOCUMENTATION; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFECTS; FUNGUS; MICROBIAL SENSITIVITY TEST; STANDARDS;

ANTIFUNGAL AGENTS; FUNGI; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

EID: 84960538917     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.01.017     Document Type: Article

References (18)

1. [1] Howard, S.J., Lass-Flörl, C., Cuenca-Estrella, M., Gomez-Lopez, A., Arendrup, M.C., Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 57 (2013), 5426–5431.
2. [2] Castanheira, M., Messer, S.A., Rhomberg, P.R., Dietrich, R.R., Jones, R.N., Pfaller, M.A., Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 178 (2014), 1–9.
3. [3] Arendrup, M.C., Jensen, R.H., Meletiadis, J., In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. Antimicrob Agents Chemother 59 (2015), 7735–7742.
4. [4] Espinel-Ingroff, A., Chowdhary, A., Gonzalez, G.M., Guinea, J., Hagen, F., Meis, J.F., et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans–Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 59 (2015), 666–668.
5. [5] Arendrup, M.C., Howard, S., Lass-Flörl, C., Mouton, J.W., Meletiadis, J., Cuenca-Estrella, M., EUCAST testing of isavuconazole susceptibility in Aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density. Antimicrob Agents Chemother 58 (2014), 6432–6436.
6. [6] Thompson, G.R., Wiederhold, N.P., Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170 (2010), 291–313.
7. [7] Maertens, J.A., Raad, I.I., Marr, K.A., Patterson, T.F., Kontoyiannis, D.P., Cornely, O.A., et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387 (2016), 760–769.
8. [8] Chen, Y., Wang, H., Lu, Z., Li, P., Zhang, Q., Jia, T., et al. Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus isolate from a Chinese patient. Antimicrob Agents Chemother 59 (2015), 7148–7150.
9. [9] Astvad, K.M.T., Jensen, R.H., Hassan, T.M., Mathiasen, E.G., Thomsen, G.M., Pedersen, U.G., et al. First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 58 (2014), 5096–5101.
10. [10] Steinmann, J., Hamprecht, A., Vehreschild, M.J.G.T., Cornely, O.A., Buchheidt, D., Spiess, B., et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 70 (2015), 1522–1526.
11. [11] Prigitano, A., Venier, V., Cogliati, M., De Lorenzis, G., Esposto, M.C., Tortorano, A.M., Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill, 19, 2014, 20747.
12. [12] Chowdhary, A., Sharma, C., Kathuria, S., Hagen, F., Meis, J.F., Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 69 (2014), 555–571.
13. [13] Pitsouni, E., Iavazzo, C., Falagas, M.E., Itraconazole vs. fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 198 (2008), 153–160.
14. [14] Graybill, J.R., Vazquez, J., Darouiche, R.O., Morhart, R., Greenspan, D., Tuazon, C., et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 104 (1998), 33–39.
15. [15] Wilcox, C.M., Darouiche, R.O., Laine, L., Moskovitz, B.L., Mallegol, I., Wu, J., A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176 (1997), 227–232.
16. [16] Urünsak, M., Ilkit, M., Evrüke, C., Urünsak, I., Clinical and mycological efficacy of single-day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis. Mycoses 47 (2004), 422–427.
17. [17] Rex, J.H., Pfaller, M.A., Galgiani, J.N., Bartlett, M.S., Espinel-Ingroff, A., Ghannoum, M.A., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing. Clin Infect Dis 24 (1997), 235–247.
18. [18] Takesue, Y., Oda, S., Fujishima, S., Mikamo, H., Aikawa, N., Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care. J Infect Chemother 18 (2012), 515–521.